Literature DB >> 35266952

Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.

Ian F Tannock1, Gregory R Pond2, Christopher M Booth3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35266952     DOI： 10.1001/jamaoncol.2021.8206

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  2 in total

1.  Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?

Authors:  Shenmiao Yang; Neil E Kay; Min Shi; Curtis A Hanson; Robert Peter Gale
Journal:  Leukemia       Date:  2022-09-13       Impact factor: 12.883

2.  The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration.

Authors:  Corinne Jamoul; Laurence Collette; Elisabeth Coart; Koenraad D'Hollander; Tomasz Burzykowski; Everardo D Saad; Marc Buyse
Journal:  BMC Med Res Methodol       Date:  2022-10-05       Impact factor: 4.612
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.